Aug 27 (Reuters) - ImmunoVaccine Inc:
* Announces 2010 second quarter results
* Q2 revenue C$6000
* Says lead product dpx-0907, a therapeutic cancer vaccine, is on track to
complete a phase i clinical trial in 2011
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Announces 2010 second quarter results
* Q2 revenue C$6000
* Says lead product dpx-0907, a therapeutic cancer vaccine, is on track to
complete a phase i clinical trial in 2011
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.